The optimal treatment strategy for patients with moderate tricuspid regurgitation (TR) present at the time of surgery to treat primary mitral regurgitation (MR) remains unclear, with “trade-offs” between longer, and therefore riskier, surgery time and potential, but still uncertain, long-term benefit.